Hosted on MSN1mon
Clinical trial: Adjuvant tamoxifen may reduce recurrence risk for patients with 'good-risk' DCIS who forgo radiation"Tamoxifen, radiation, or both, as well as the omission of any adjuvant therapy, are all reasonable options," she said. "Now, we have more data to help our patients choose among these ...
This is the second installment of a three-part series on breast cancer.] The most common breast cancer symptom is a lump. Other symptoms include swelling, skin irritation, nipple pain or ...
The program of therapy prescribed for you depends on several factors including: tumor size, lymph node status, cell type, hormone receptor tests, cell growth patterns, your age and health, menopausal ...
Hosted on MSN25d
Does Adjuvant Therapy Prevent Cancer Recurrence?Nolvadex (tamoxifen) is one example of a hormone therapy that can block these receptors and slow the growth of any remaining cancer. Oral therapy (taking medications by mouth) is often used in ...
For most patients, adjuvant hormone therapy is treatment with the drug tamoxifen (also called Nolvadex) for five years. Some premenopausal patients may have surgery to remove their ovaries, which are ...
breast cancer develop resistance to hormone treatment, and a potential new approach to overcome the problem. Around 80% of breast cancers are ER+ and are treated with anti-oestrogen therapies such as ...
Aromatase inhibitors work differently than Tamoxifen; they actually lower ... Earlier versions of hormone therapy sometimes caused nausea, bleeding and blood clots, but those side effects have ...
The therapies that protect you from recurrence—life-saving treatments like tamoxifen and aromatase ... For many, the side effects of hormone therapy—crippling anxiety, sexual dysfunction ...
Nat Clin Pract Oncol. 2008;5(9):531-542. The authors declared no competing interests. Cite this: The Role of Hormonal Therapy in the Management of Hormonal-Receptor-Positive Breast Cancer With Co ...
using the Functional Assessment of Cancer Therapy - Breast (FACT-B) scale and an endocrine subscale at 0 to 24 months during the study concluded that tamoxifen and anastrozole were associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results